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Abnormal metabolic network activity in
REM sleep behavior disorder
ABSTRACT
Objective: To determine whether the Parkinson disease–related covariance pattern (PDRP) expres-
sion is abnormally increased in idiopathic REM sleep behavior disorder (RBD) and whether increased
baseline activity is associated with greater individual risk of subsequent phenoconversion.
Methods: For this cohort study, we recruited 2 groups of RBD and control subjects. Cohort 1 com-
prised 10 subjects with RBD (63.56 9.4 years old) and 10 healthy volunteers (62.76 8.6 years
old) who underwent resting-state metabolic brain imaging with 18F-fluorodeoxyglucose PET.
Cohort 2 comprised 17 subjects with RBD (68.9 6 4.8 years old) and 17 healthy volunteers
(66.66 6.0 years old) who underwent resting brain perfusion imaging with ethylcysteinate dimer
SPECT. The latter group was followed clinically for 4.6 6 2.5 years by investigators blinded to
the imaging results. PDRP expression was measured in both RBD groups and compared with
corresponding control values.
Results: PDRP expression was elevated in both groups of subjects with RBD (cohort 1: p , 0.04;
cohort 2: p , 0.005). Of the 17 subjects with long-term follow-up, 8 were diagnosed with
Parkinson disease or dementia with Lewy bodies; the others did not phenoconvert. For individual
subjects with RBD, final phenoconversion status was predicted using a logistical regression
model based on PDRP expression and subject age at the time of imaging (r25 0.64, p, 0.0001).
Conclusions: Latent network abnormalities in subjects with idiopathic RBD are associated with a
greater likelihood of subsequent phenoconversion to a progressive neurodegenerative syndrome.
Neurology® 2014;82:620–627
GLOSSARY
DLB 5 dementia with Lewy bodies; ECD 5 ethylcysteinate dimer; FDG 5 18F-fluorodeoxyglucose; MSA 5 multiple system
atrophy; PD 5 Parkinson disease; PDRP 5 Parkinson disease–related covariance pattern; RBD 5 REM sleep behavior dis-
order; VOI 5 volume of interest.
REM sleep behavior disorder (RBD) can occur in isolation, but many individuals develop a
defined neurodegenerative syndrome within 5 years of diagnosis.1,2 Most often, phenoconver-
sion is a manifestation of underlying Lewy body pathology as seen in idiopathic Parkinson
disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).3
Many neurodegenerative diseases, including those associated with RBD, exhibit stereotyped
changes in brain structure and function that occur at the systems level.4 Indeed, network analysis
of resting-state functional imaging data has revealed distinct spatial covariance topographies that
characterize these disorders.5–7 Idiopathic PD is a case in point. This disorder is associated with a
highly reproducible disease-related metabolic brain network, known as the PD-related covari-
ance pattern (PDRP).5,7–9 The PDRP topography (figure 1) is characterized by increases in
pallidothalamic, pontine, and cerebellar metabolic activity and by reductions in premotor and
parietal association regions. Progressive motor disability in patients with PD is accompanied
by continuous increases in PDRP expression,5,10 consistent with a close relationship between
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network activity and clinical manifestations in
individuals with this disorder.5,6 Nonetheless,
network activity was found to be elevated
in the “presymptomatic” hemisphere (i.e.,
ipsilateral to the symptomatic body side) in
patients with early-stage PD with unilateral
motor involvement (“hemi-PD”), anteceding
the onset of contralateral limb manifestations
by several years.11
In this study, we used functional imaging to
determine whether analogous prodromal net-
work abnormalities were present in individuals
with idiopathic RBD and whether abnormal
network expression was a predictor of subse-
quent phenoconversion.
METHODS Subjects. We studied 2 discrete groups of subjects
with RBD who were diagnosed according to established criteria.12
Exclusion criteria were signs or symptoms of other neurologic dis-
eases and RBD secondary to other diseases or medication. Cohort
1 comprised 10 subjects with RBD recruited at the sleep disorders
clinics of the North Shore-Long Island Jewish Health System
(Manhasset, NY) and the Hospital of the University of
Pennsylvania (Philadelphia) between November 2010 and May
2013. These individuals and 10 healthy age-matched volunteer
subjects (62.7 6 8.6 years old) underwent metabolic brain
imaging with 18F-fluorodeoxyglucose (FDG)-PET to evaluate
resting metabolic activity at both the network and region (nodal)
levels. Cohort 2 comprised a second group of subjects with RBD
who were recruited at the Sleep Disorders Clinic of the Hôpital du
Sacré-Coeur de Montréal (Canada) between February 2003 and
July 2008. These subjects and 17 healthy age-matched volunteers
(66.66 6.0 years old) underwent cerebral perfusion imaging with
99mTc ethylcysteinate dimer (ECD) and SPECT. Limited clinical
and imaging data from these subjects have been presented
previously.13,14 In this study, we used the scan data from cohort
2 to validate the functional brain changes discerned in the first
cohort.
Scan data from cohort 2 were additionally used to determine
whether the presence of baseline functional abnormalities in indi-
viduals with idiopathic RBD was associated with subsequent phe-
noconversion, as determined by the later development of a
defined neurodegenerative syndrome. After baseline imaging,
subjects with RBD in this cohort were followed annually by a
movement disorders neurologist (R.B.P.) and a neuropsychologist
(J.-F.G.). Eight members of this cohort subsequently developed
parkinsonism, and were diagnosed with either PD (n 5 5) or
DLB (n5 3) according to established criteria.15,16 The remaining
9 subjects with RBD in this group did not phenoconvert during
the follow-up period.
Apart from the 17 subjects with RBD in cohort 2, we ana-
lyzed baseline ECD SPECT data from 3 additional subjects with
idiopathic RBD who subsequently developed signs of atypical
parkinsonism. These subjects were diagnosed with probable
(n 5 1) or possible (n 5 2) MSA according to consensus crite-
ria.17 Given that the histopathology of MSA is different from PD/
DLB, and that this neurodegenerative phenotype develops less
frequently in idiopathic RBD,12 these subjects were analyzed as a
discrete diagnostic category (see below).
Imaging procedures. Cohort 1 subjects underwent metabolic
imaging with FDG-PET in an eyes-open resting state as
detailed elsewhere.8 Subjects recruited at North Shore-Long
Island Jewish Health System (n 5 5) were scanned on a GE
Advance tomograph (General Electric, Milwaukee, WI).
Subjects recruited at the University of Pennsylvania (n 5 5)
were scanned on a Biograph 40 mCT-S PET/CT device
(Siemens Medical Solutions, Knoxville, TN). Cohort 2 subjects
underwent perfusion imaging with ECD SPECT in a similar
awake state as previously described.13 These subjects were
scanned using the 3-headed SPECT camera (PRISM system;
Picker Co., Cleveland, OH) at Hôpital du Sacré-Coeur de
Montréal in Montreal, Canada.
Figure 1 Parkinson disease–related spatial covariance pattern
This abnormal brain network is characterized by increased metabolic activity in the pons, cerebellum, globus pallidus inter-
nus (GP), putamen (Put), ventral thalamus, and primary motor cortex and relative reductions in the lateral premotor and pari-
etal association regions. The color stripe represents region weights (voxel loadings) on the network. Positive voxel weights
(denoting regions with increased metabolic activity) are color-coded from red to yellow. Negative voxel weights (denoting
regions with reduced metabolic activity) are color-coded from blue to green. The left side (L) is indicated for each slice. Co-
ordinates correspond to the Montreal Neurological Institute standard space.
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Network measurements. Preprocessing of the scan data was
performed using SPM 5 (Wellcome Department of Cognitive
Neurology, London, UK) implemented in MATLAB (Math-
Works, Sherborn, MA). Images were spatially normalized and
smoothed (full width at half maximum 10 3 10 3 10 mm for
FDG-PET; 14 3 14 3 14 mm for ECD SPECT). PDRP
expression values, reflecting whole-brain network activity in
each subject, were computed using an automated voxel-based
algorithm (software available at http://www.fil.ion.ucl.ac.uk/
spm/ext/#SSM).5,9,18 Measurements of whole-brain PDRP
expression were standardized by z scoring with respect to
corresponding values from healthy subjects scanned under the
same tomographic conditions. This permitted the comparison
of network changes across imaging modalities.9,18
In cohort 1, the PDRP scores were standardized based on val-
ues computed in FDG-PET scans from the corresponding
healthy reference group as described elsewhere.9,18 We also com-
puted network activity in cohort 1 subjects on a hemisphere-by-
hemisphere basis.11 For each subject, right and left hemisphere
PDRP values were z scored with respect to corresponding hemi-
spheric measurements from the healthy control group. For RBD
and healthy control subjects, right and left hemisphere PDRP
measurements were averaged and compared with analogous val-
ues computed in the preclinical (ipsilateral) hemispheres of sub-
jects with early-stage PD and unilateral symptoms. This
previously reported cohort comprised 15 subjects with
hemi-PD who were scanned with FDG-PET at baseline and
again, 2 and 4 years later.11
In cohort 2, we used the same procedure to compute whole-
brain PDRP values in the ECD SPECT data.19,20 PDRP values
computed in this sample were standardized with respect to cor-
responding measurements from the healthy control subjects for
this cohort. As in cohort 1, these automated computations were
performed on an individual case basis, blinded to group mem-
bership and final clinical status.
In both cohorts, a regional analysis was conducted to assess
group differences in resting brain function at the major nodes of
the PDRP network. Volumes of interest (VOIs)8 were defined
by 4-mm spheres centered at nodal maxima (table 1) situated in
the pons, cerebellum, putamen/globus pallidus, and thalamus and
in sensorimotor, lateral premotor, and parietal association cortex.
A single midline VOI was placed in the pons and cerebellar vermis;
separate right and left VOIs were delineated for the other regions,
which were averaged for further analysis. In each VOI, local activ-
ity was ratio normalized by the global value for the corresponding
scan. Group differences in PDRP expression and in local activity at
each node were assessed using 2-tailed Student t tests.
Logistical regression analysis. Logistical regression analysis
was used to determine whether baseline measurements of PDRP
expression correlated with the likelihood of subsequent pheno-
conversion in the RBD follow-up cohort (cohort 2). In these
subjects, the individual network values were sealed before the
final clinical status of the participants was released. We first
tested a 2-category predictive model in which phenoconverters
to PD/DLB (n 5 8) were defined as one classification group,
while the nonphenoconverters (n 5 9) were defined as the other
group. We also tested a 3-category model that included the
3 phenoconverters to possible or probable MSA as a separate
classification group. Model selection was based on relative
goodness of fit as determined by the Akaike Information
Criterion.21 Categorization accuracy was assessed using
likelihood-ratio tests. Group differences in PDRP expression
and in regional activity at the major network nodes were
evaluated using SPSS software (SPSS Inc., Chicago, IL).
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Logistical regression analysis was performed using SAS 9.1
software (SAS Institute Inc., Cary, NC). Results were
considered significant for p , 0.05.
Standard protocol approvals, registrations, and patient
consents. Ethical permission for the procedures was obtained
from the Institutional Review Board of North Shore University
Hospital, Hospital of the University of Pennsylvania, and Hô-
pital du Sacré-Coeur de Montréal. Written consent was ob-
tained from each participant after a detailed explanation of
the procedures.
RESULTS Clinical follow-up. Demographic and clini-
cal data from cohort 1 and cohort 2 subjects with RBD
are summarized in table e-1 on the Neurology® Web
site at www.neurology.org. For the 8 subjects with
RBD in cohort 2 who subsequently were diagnosed
with PD/DLB, the mean interval between imaging and
time of diagnosis was 3.4 6 2.1 years (range, 0.4–6.2
years). The mean interval between imaging and final
clinical assessment in the nonphenoconverters was 5.
6 6 2.4 years (range, 3.9–11.3 years) and 4.6 6 2.
5 years (range, 0.4–11.3 years) for the whole cohort.
Three additional subjects with RBD (50, 61, and 66
years old; Unified Parkinson’s Disease Rating Scale
motor ratings 0, 2.5, and 2) were diagnosed with
possible or probable MSA and developed signs of
atypical parkinsonism 4.3, 2.5, and 2.7 years after
imaging. (In cohort 1, the mean duration of clinical
follow-up after imaging was 1.36 0.7 years [range, 0–
2.2 years]; none of the subjects with RBD in this
cohort have phenoconverted as of August 2013.)
Elevated PDRP expression in idiopathic RBD. PDRP
expression (figure 2, A and B) was elevated in each
of the RBD cohorts relative to corresponding healthy
control values (cohort 1: 0.83 6 0.18 [mean 6 SE],
p, 0.04; cohort 2: 1.046 0.23, p5 0.004, Student
t tests). In cohort 1, the range of network values seen
in the subjects with RBD was similar for the 2 imag-
ing sites (North Shore: 0.12–1.55; University of
Pennsylvania: 0.09–1.38).
In cohort 2, baseline network activity was higher
in the subjects with RBD who subsequently pheno-
converted to PD or DLB (n 5 8) relative to those
who did not phenoconvert (n5 9) during the follow-
up period (p , 0.03). In both cohorts, the subjects
with RBD displayed increases in PDRP expression
that were similar to values measured in the preclinical
hemispheres of patients with early-stage PD with uni-
lateral motor signs (figure 2A, right). Given the con-
cordance of the PDRP changes observed in RBD
cohort 1 and cohort 2, the network abnormality
was robust (0.966 0.16, p, 0.001) when data from
the 2 samples were merged.
Figure 2 Elevated network activity in subjects with RBD
(A) In cohort 1, PDRP expression was quantified in scans of cerebral metabolic activity obtained in 10 subjects with RBD and
10 age-matched NL subjects. In this cohort, PDRP expression (left panel) was abnormally elevated in the RBD group (p ,
0.04). Network activity in these subjects was comparable to corresponding measures computed in the preclinical hemi-
spheres of a separate cohort of patients with hemiparkinsonism (see text). *p, 0.005, **p, 0.001 compared with healthy
controls; Student t test. (B) Similar network changes were observed in cohort 2, in which PDRP expression was quantified in
cerebral perfusion scans from 17 individuals with RBD and 17 age-matched NL subjects. Abnormal elevations in network
activity were observed in this RBD group (p 5 0.004) at levels comparable to those measured in the first cohort. In RBD
cohort 1 and in the hemi-PD cohort, PDRP scores were computed in FDG-PET scans and standardized with respect to
corresponding values from 10 age-matched healthy control subjects. In cohort 2, network expression values computed in
ECD SPECT scans were standardized according to the corresponding values from 17 NL subjects (see text). The error bars
indicate the SEM. ECD 5 ethylcysteinate dimer; FDG 5 18F-fluorodeoxyglucose; NL 5 normal control; PD 5 Parkinson
disease; PDRP 5 Parkinson disease–related covariance pattern; RBD 5 REM sleep behavior disorder.
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Group comparison of resting activity at the major
PDRP nodes (table 1) revealed consistent regional
changes in both RBD groups. Relative to healthy indi-
viduals, subjects with RBD exhibited consistent increases
in nodal activity (figure 3, A–D) in the pons (cohort 1:
p 5 0.021; cohort 2: p 5 0.002) and in the putamen/
globus pallidus (cohort 1: p 5 0.016; cohort 2: p 5
0.047; Student t tests). Of note, local pontine activity
(figure 3B, right) was greater in the subjects with RBD
who later phenoconverted to PD/DLB relative to their
nonphenoconverter counterparts (p, 0.001). Marginal
elevations in nodal activity were observed in the thala-
mus (cohort 1: p5 0.041; cohort 2: p5 0.061) and the
cerebellum (cohort 1: p5 0.058; cohort 2: p5 0.022).
The latter node also exhibited a trend-level increase in
the phenoconverters relative to the nonphenoconverters
(p 5 0.061). Differences in functional activity in the
RBD and healthy control groups and between pheno-
converters and nonphenoconverters were not significant
in the other network regions (p . 0.24).
Network activity: A predictor of later phenoconversion.
Using logistic regression, we first constructed a
2-category predictive model based on PDRP
expression in which each subject was classified as
either likely to phenoconvert to PD or DLB or as
unlikely to phenoconvert. This model exhibited a
good fit to the data, accounting for 27.6% of the
variance in final clinical status (p , 0.02). Review of
the individual data revealed high baseline network
activity (subject scores $0.90) in each of the 8
subjects with RBD who subsequently phenoconverted
to PD or DLB. Network elevations of similar
magnitude were, however, also seen in 3 of the 9
subjects who did not phenoconvert during the follow-
up period (figure 4A, arrows). A second predictive
model based on subject age at the time of imaging
had comparable goodness of fit, accounting for 23.7%
of the variance in outcome (p , 0.04). Notably, the
correlation between these 2 variables was not significant
(p5 0.58), suggesting their independence as predictors
Figure 3 Nodal analysis
(A, B) Regional activity measured at the pontine node of the Parkinson disease–related covariance pattern network was elevated in both RBD cohorts relative
to corresponding NL values (cohort 1: p, 0.03; cohort 2: p5 0.002, Student t tests). In this region (B, right panel), local activity was higher (p, 0.001) in the
cohort 2 subjects with RBD who later phenoconverted to PD or DLB (CON[1]) than in those who did not phenoconvert (CON[2]) to a defined neurodegen-
erative syndrome. (C, D) Modest regional elevations (p , 0.05) were also noted at the putamen/GPi node of the 2 RBD cohorts. Nonetheless, the difference
between CON(1) and CON(2) subjects in cohort 2 (D, right panel) was not significant (p 5 0.59). The error bars represent the SEM. DLB 5 dementia with
Lewy bodies; GPi 5 globus pallidus internus; NL 5 normal control; PD 5 Parkinson disease; Put 5 putamen; RBD 5 REM sleep behavior disorder.
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of phenoconversion in RBD. Indeed, goodness of fit
improved substantially when both PDRP expression
and subject age were entered together into a 2-category
predictive model, accounting for 64.0% of the
individual differences in phenoconversion status (p ,
0.001). Graphical display of the data according to this
model (figure 4B) revealed substantial improvement in
categorization accuracy, with excellent discrimination
between phenoconverters to PD/DLB (blue ellipse)
and nonphenoconverters (red ellipse).
Finally, we used this approach to classify the 3 sub-
jects with RBD who later phenoconverted to possible
or probable MSA. Although the 2-category predictive
model was derived from phenoconverters to PD/
DLB and nonphenoconverters, the phenoconverters
to MSA formed a discrete cluster (green ellipse) based
on their low (subnormal) network activity and rela-
tively young age at the time of imaging. A 3-category
logistical model based on the data (figure 4B) had
excellent goodness of fit, correctly classifying 19 of
20 (95%) of the subjects with RBD (p , 0.0001).
DISCUSSION In this study, we report elevated expres-
sion of the PDRP, an abnormal disease-related
metabolic brain network, in subjects with idiopathic
RBD. Indeed, significant increases in network activity
were found in 2 separate RBD cohorts, at levels
consistent with prodromal PD. Long-term clinical
follow-up data suggested that phenoconversion was
more likely in individual RBD subjects with network-
level functional abnormalities at baseline.
The current study extends the prior observations of
dopaminergic deficits in RBD and the relationship of
these changes to incipient PD.22,23 Of note, the PDRP
network has several advantages compared with dopa-
minergic imaging techniques. While PDRP expression
is associated with both presynaptic nigrostriatal dopa-
minergic dysfunction and Unified Parkinson’s Disease
Rating Scale motor ratings,6,24 it is worth noting that
the magnitude of these correlations is modest. Indeed,
individual differences in any of these descriptors
account for no more than one-third of the variation
in the other 2 measures.10 It is therefore likely that the
PDRP increases seen in some subjects with RBD
denote a specific functional aspect of the disease pro-
drome that is not captured by striatal dopamine trans-
porter binding measurements. In this vein, the PDRP
changes may also distinguish future phenoconverters
to PD/DLB from MSA—conditions not readily dis-
tinguished based on dopaminergic imaging meas-
ures.25,26 A direct comparison of dopaminergic
imaging and network quantification techniques will
be needed to clarify the strengths and weaknesses of
the 2 scanning strategies.
It is also noteworthy that abnormal elevations in
PDRP expression in subjects with RBD were
observed using metabolic imaging with FDG-PET
and substantiated in scans of cerebral perfusion using
ECD SPECT. Indeed, we have found consistent net-
work abnormalities in patients with PD scanned
Figure 4 Classification of subjects with RBD based on PDRP expression and age
at the time of imaging
(A) PDRP expression was elevated in the cohort 2 subjects with RBD who subsequently
developed clinical manifestations of PD or DLB (black diamonds) relative to those who did
not phenoconvert (CON[2]) (black triangles). The 3 subjects with RBD (black squares) who
subsequently developed possible or probable MSA exhibited negative network scores, indic-
ative of expression levels that were below the normal mean. The 3 nonphenoconverters with
high baseline PDRP expression are demarcated by arrows (see text). (B) Logistical regression
analysis using a combination of PDRP expression values and age at the time of imaging (see
methods section) accurately classified the subjects (p, 0.0001) as either phenoconverters
to PD/DLB (blue ellipse) or MSA (green ellipse) or as nonphenoconverters (red ellipse). DLB5
dementia with Lewy bodies; MSA 5 multiple system atrophy; PD 5 Parkinson disease;
PDRP5 Parkinson disease–related covariance pattern; RBD5 REM sleep behavior disorder.
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using the latter approach.19,20 The PDRP abnormality
seen in both RBD cohorts accords well with the tight
coupling that has been observed between network
expression values in scans of cerebral blood flow
and metabolism obtained in the same subjects.8,27
Nonetheless, FDG-PET and ECD SPECT data
are not interchangeable and thus were analyzed
separately.
In aggregate, our data comport with the view of
RBD as the prodromal phase of a progressive
systems-based neurodegenerative process.1–3,28 Fur-
ther support is provided by the nodal measurements,
which showed that regional abnormalities in the 2
RBD groups were most pronounced caudally in the
pons, and that changes rostrally in the basal ganglia
and thalamus were less consistent. Indeed, significant
functional abnormalities were not evident in cortical
PDRP network regions in either RBD cohort. This
pattern is consistent with an ascending disease pro-
cess.29 Of note, we have previously reported signifi-
cant metabolic abnormalities in the dorsal pons at the
earliest clinical stages of PD, which increased rapidly
with disease progression.10 The underlying causes for
the pontine abnormality of RBD are unknown. That
this regional change was most pronounced in the
phenoconverters to PD/DLB, i.e., the subjects with
RBD who later developed clinical manifestations of
Lewy body pathology, suggests a direct association
with the neurodegenerative process itself. Nonethe-
less, a small nonsignificant increase in pontine activity
was also present in the nonphenoconverters (figure
3B, right), compatible with the modulatory role that
has been proposed for this region in the pathophysi-
ology of RBD.28
While PDRP expression and subject age each pro-
vided critical information regarding the likelihood of
subsequent phenoconversion, final clinical status was
predicted more accurately by the 2 measures in con-
cert. In this context, subject age proved useful as an
adjunct to network activity in predicting individual
case outcomes. This point is illustrated by the 3 non-
phenoconverters with relatively increased PDRP
expression (figure 4A, arrows). Given that these values
did not differ from those of the subjects with RBD
who later phenoconverted to PD/DLB, these data rep-
resent false-negative misclassifications based on the
network measurements alone. We note, however, that
these individuals were correctly classified once age was
taken into account. Thus, despite relatively high base-
line network expression levels, these subjects were
likely too young for phenoconversion to have occurred
during the ensuing 5 years of clinical follow-up. In fact,
based on the 2-category logistical model, these individ-
uals were unlikely to exhibit a manifest neurodegener-
ative phenotype for another 2 to 3 years (i.e., 4–5 years
after baseline imaging; figure 4B, arrows).
Two further points are germane to network-based
predictions in subjects with idiopathic RBD. First,
PDRP expression was similar for RBD phenoconvert-
ers to PD and DLB (1.42 6 0.28 [mean 6 SE] and
1.79 6 0.42, respectively). This observation is com-
patible with the substantial histopathologic and neu-
rochemical overlap that has been observed between
patients with PD, with or without dementia, and
DLB.30,31 Given preliminary data suggesting compa-
rable PDRP abnormalities in patients with PD and
DLB (L. Teune, personal communication), it is per-
haps not surprising that the phenoconverters to PD
and DLB constituted a homogeneous group regard-
ing this particular network. Second, the 2-variable
logistical model correctly classified the 3 subjects with
RBD who subsequently phenoconverted to possible/
probable MSA. This accords with the low PDRP
expression values seen in patients with MSA.32
Indeed, the 3 atypical phenoconverters exhibited neg-
ative subject scores, denoting subnormal network
activity, which discriminated them from the other
subjects with RBD. Moreover, in agreement with
the earlier onset of MSA relative to PD/DLB,33 these
individuals proved to be younger than phenoconvert-
ers to PD or DLB (baseline age5 58.86 8.3 years vs
71.4 6 4.3 years). This factor, in addition to low
network activity, explains the discrete clustering of
the data from these subjects with RBD. Needless to
say, rigorous validation studies will be needed before
this or other predictive algorithms can be used reliably
to predict clinical outcome in individuals with iso-
lated RBD.
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